|
Video: What is a Stock Split?
|
|
Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3. According to our CRIS split history records, Curis has had 2 splits. | |
|
Curis (CRIS) has 2 splits in our CRIS split history database. The first split for CRIS took place on May 30, 2018. This was a 1 for 5 reverse split, meaning for each 5 shares of CRIS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split. CRIS's second split took place on September 29, 2023. This was a 1 for 20 reverse split, meaning for each 20 shares of CRIS owned pre-split, the shareholder now owned 1 share. For example, a 200 share position pre-split, became a 10 share position following the split.
When a company such as Curis conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CRIS split history from start to finish, an original position size of 1000 shares would have turned into 10 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Curis shares, starting with a $10,000 purchase of CRIS, presented on a split-history-adjusted basis factoring in the complete CRIS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/18/2024 |
|
Start price/share: |
$247.00 |
|
End price/share: |
$15.22 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-93.84% |
|
Average Annual Total Return: |
-24.33% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$615.98 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
05/30/2018 | 1 for 5 | 09/29/2023 | 1 for 20 |
|
|